|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1B
|
|
pubmed:dateCreated |
2001-4-12
|
|
pubmed:abstractText |
We have previously demonstrated that tamoxifen enhanced the chemosensitivity of bladder cancer cells in vitro. In this pilot study, we tested the modulating effect of high-dose tamoxifen to conventional cisplatin, methotrexate, and vinblastine combination chemotherapy (CMV-T) for transitional cell carcinoma (TCC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0250-7005
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
711-5
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11299831-Aged,
pubmed-meshheading:11299831-Aged, 80 and over,
pubmed-meshheading:11299831-Anemia,
pubmed-meshheading:11299831-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11299831-Carcinoma, Transitional Cell,
pubmed-meshheading:11299831-Cisplatin,
pubmed-meshheading:11299831-Drug Administration Schedule,
pubmed-meshheading:11299831-Female,
pubmed-meshheading:11299831-Gastrointestinal Diseases,
pubmed-meshheading:11299831-Humans,
pubmed-meshheading:11299831-Male,
pubmed-meshheading:11299831-Methotrexate,
pubmed-meshheading:11299831-Middle Aged,
pubmed-meshheading:11299831-Neutropenia,
pubmed-meshheading:11299831-Remission Induction,
pubmed-meshheading:11299831-Sepsis,
pubmed-meshheading:11299831-Tamoxifen,
pubmed-meshheading:11299831-Thrombocytopenia,
pubmed-meshheading:11299831-Treatment Outcome,
pubmed-meshheading:11299831-Urinary Bladder Neoplasms,
pubmed-meshheading:11299831-Vinblastine
|
|
pubmed:articleTitle |
Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma.
|
|
pubmed:affiliation |
Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
